View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Carole Braudeau
  • Carole Braudeau

Morning Crédit 11/11/2024

Q4 23 results: Conti lowers guidance again, albeit adj. EBIT improves Kion : new EUR 500m senior unsecured bond>...

Carole Braudeau
  • Carole Braudeau

Credit Morning 11/11/2024

Q4 23 results: Conti lowers guidance again, albeit adj. EBIT improves Kion : New EUR 500m senior unsecured bond>...

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir

Recordati : Operating performance holding up well despite the top-line...

>Rare diseases are a growth driver - Recordati reported on Friday during trading its figures for Q3 2024. Sales over the period are 2.8% below forecasts at € 557.4m (+9% y-o-y). We highlight: i/ growth momentum still driven by the rare diseases segment (+14.5% cc) for 9M, with business continuing to benefit from endocrinology (+36%) and oncology (+17%); ii/ growth in the SPC franchise is still robust at 9% (+6.5% cc), but more impacted than expected by the Cough&Cold ...

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir

Recordati : Performance opérationnelle au rendez-vous malgré une topli...

>Les maladies rares en locomotive de la croissance - Recordati a publié vendredi en séance ses chiffres au titre du T3 2024. Les ventes sur la période ressortent 2.8% inférieures aux attentes à 557.4 M€ (+9% yoy). Nous soulignons i/ une dynamique de croissance toujours tirée par le segment des maladies rares (+14,5% tcc) sur les 9 premiers mois, l'activité continue de bénéficier de l'endocrinologie (+36%) et de l'oncologie (+17%), ii/ la croissance de la franchise SPC...

Haidje Rustau ... (+6)
  • Haidje Rustau
  • Ian Wong
  • Jayanth Kandalam
  • Peter Low
  • Si Yong Ng
  • Trung Nguyen

Lucror Analytics - Morning Views Europe

In today's Morning Views publication we comment on developments of the following high yield issuers: Nexans, Recordati, TeamSystem, Stada, CMA CGM, Nexi, Vedanta Resources, Fedrigoni, Modulaire, TI Fluid Systems, Iceland Foods, United Group, Standard Profil, Selecta, Italmatch Chemicals

 PRESS RELEASE

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2...

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5% Consolidated net revenue of € 1,743.1 million in the first nine months, +12.0% or +9.3% on a like-for-like basis(3) and at constant exchange rates (CER)EBITDA(1) of € 665.7 million, +11.8%, revenue margin of 38.2%         Adjusted net income(2) of € 445.4 million, +9.5% Net income of € 338.4 million, +11.1% Free cash flow(4) at € 434.3 million, +€ 42.5 million vs prior yearNet debt(5) at € 1,317.3 million, just below 1.6x EBITDAFinancial targets for FY...

Felix Fischer ... (+5)
  • Felix Fischer
  • Ian Wong
  • Jayanth Kandalam
  • Peter Low
  • Tanvi Arora

Lucror Analytics - Morning Views Europe

In today's Morning Views publication we comment on developments of the following high yield issuers: Recordati, Teva, Novelis, Bombardier, Selecta, Hapag-Lloyd, Italmatch Chemicals, Kem One, Cirsa, Nexans, ASK Chemicals, Borr Drilling, Encore Capital (formerly Cabot)

Carole Braudeau
  • Carole Braudeau

Credit Morning 10/07/2024

Elis has ended discussions with Vestis and UniFirst Ubisoft: Tencent and the Guillemot family are said to weigh various scenarios including a buyout (Bloomberg)ZF Friedrichshafen : short-term rating pressure from Moody’s Advanz Pharma : deep-pocket Ontario Teacher’s Pension Plan steps back from potential stake>...

Carole Braudeau
  • Carole Braudeau

Morning Crédit 07/10/2024

Elis a mis fin aux discussions avec Vestis et UniFirst Ubisoft : Tencent et la famille Guillemot réfléchiraient à différents scénarios dont un rachat de la société (Bloomberg)ZF Friedrichshafen : short-term rating pressure from Moody’s Advanz Pharma : deep-pocket Ontario Teacher’s Pension Plan steps back from potential stake >...

Bruno Cavalier ... (+2)
  • Bruno Cavalier
  • Jerôme Bodin

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 10/07/2024

Last week we held our fourth ODDO BHF Iberian Forum. The event was fully virtual and took place on October 1 and 2. With 62 Iberian issuers, close to 200 institutional investors and c. 800 meetings, this is one of the largest dedicated Iberian conferences held this year. This note brings together 49 feedback documents, with 5 target price revisions (o/w 3 downward revisions) and a rating downgrade on Pharma Mar. The main subjects of debate were i/ the trend in final demand in the con...

Bruno Cavalier ... (+2)
  • Bruno Cavalier
  • Jerôme Bodin

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 07/10/2024

Last week we held our fourth ODDO BHF Iberian Forum. The event was fully virtual and took place on October 1 and 2. With 62 Iberian issuers, close to 200 institutional investors and c. 800 meetings, this is one of the largest dedicated Iberian conferences held this year. This note brings together 49 feedback documents, with 5 target price revisions (o/w 3 downward revisions) and a rating downgrade on Pharma Mar. The main subjects of debate were i/ the trend in final demand in the con...

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir

Recordati : Recordati further strengthens rare diseases franchise

>Acquisition of Enjaymo in cold agglutinin disease - Recordati on Friday announced a fresh acquisition for € 825m (+ up to € 250m in commercial milestones) with Enjaymo (sutimlimab), a monoclonal antobody developed by Sanofi in the treatment of cold agglutinin disease, a rare form of anaemia. The treatment, the only drug specifically approved in this indication, has generated sales of € 100m over the last 12 months (in the US, Europe and Japan).We see this a stra...

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir

Recordati : Recordati renforce une nouvelle fois sa franchise maladies...

>Acquisition d’Enjaymo dans la maladie des agglutinines froides - Recordati a annoncé vendredi dernier une nouvelle acquisition pour 825 M€ (+ jusqu’à 250 M€ de milestones commerciaux) d’Enjaymo (sutimlimab), un anticorps monoclonal développé par Sanofi dans le traitement de la maladie des agglutinines froides, une forme d’anémie rare. Le traitement, seul produit approuvé spécifiquement dans cette indication, a généré environ 100 M€ sur les 12 derniers mois (aux Etats...

Carole Braudeau
  • Carole Braudeau

Credit Morning 08/09/2024

Eutelsat: 2023-24 EBITDA above guidance but weak prospects for 2024-25>...

Carole Braudeau
  • Carole Braudeau

Morning Crédit 09/08/2024

Eutelsat : EBITDA 2023-24 supérieur à la guidance. Les perspectives 2024-25 sont faibles>...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch